TB-500 is a synthetic peptide related to the actin-binding region of Thymosin Beta-4 (TΞ²4), a naturally occurring 43-amino-acid peptide found throughout mammalian tissues. Thymosin Beta-4 is the major actin-sequestering molecule in mammalian cells, and because a short internal sequence of the parent molecule carries much of its actin-binding activity, TB-500 has become a widely used laboratory reference compound for studying the repair-related biology associated with TΞ²4.
What keeps TB-500 and Thymosin Beta-4 at the center of repair-peptide research is not a single dramatic effect but the breadth of the cellular processes the parent peptide appears to touch β cell migration, blood-vessel formation, cell survival and inflammatory signaling. This guide summarizes what the peer-reviewed literature reports about those mechanisms, notes the 2026 regulatory context, and β just as importantly β is explicit about where the evidence is still thin.
Thymosin Beta-4 was first characterized as a housekeeping protein that binds monomeric G-actin, helping to regulate the assembly and disassembly of the actin cytoskeleton β the internal scaffolding that lets cells change shape and move. Because coordinated cell movement is fundamental to wound closure and tissue remodeling, researchers have described TΞ²4 as an actin-regulating protein that "moonlights" in tissue repair. TB-500 is used to probe that actin-binding function specifically, which is why the two names are so often discussed together in the research literature.
Across in-vitro and animal-model studies, Thymosin Beta-4 (and TB-500 as its actin-binding fragment) has been associated with a range of activities. Each of the following is drawn from laboratory or preclinical research β none should be read as an established human clinical outcome:
In a widely cited review of animal work, Thymosin Beta-4 was described as a "multifunctional tissue repair and regeneration peptide," with its benefits in wound-healing models attributed to this combination of pro-migratory, pro-angiogenic, pro-survival and anti-inflammatory actions rather than to any single pathway.
Most therapeutics are designed to hit one receptor or one metabolic pathway. The interest in Thymosin Beta-4 and TB-500 comes from the opposite direction: in the models studied the peptide influences several processes at once β cell movement, vessel formation, cell survival and inflammation control β apparently by acting on the actin cytoskeleton that underlies all of them. This "many processes, one upstream lever" behavior is a recurring theme in the literature and is a large part of why TB-500 became a reference compound in soft-tissue, vascular and musculoskeletal research.
On July 23β24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to evaluate a group of peptides being considered for inclusion on the 503A bulk drug substances list β the list of substances that compounding pharmacies may use. TB-500 (as free base and acetate forms), with wound healing listed as the evaluated use, was among the substances reviewed, alongside peptides such as BPC-157, KPV and MOTS-c.
It is important not to over-read this. A PCAC review concerns whether a substance may be eligible for pharmacy compounding under specific conditions; it is a distinct process from FDA approval of a marketed medicine. Regardless of that process, the products Universe Peptide supplies are sold strictly as research chemicals for in-vitro laboratory use and are not offered for compounding, prescribing or any human or animal use.
This is the part responsible sourcing pages should state plainly. The in-vitro and animal-model evidence for Thymosin Beta-4 is genuinely substantial, spanning cell-migration assays, angiogenesis studies and dermal, corneal and cardiac wound-repair models over many years. Human clinical work with Thymosin Beta-4 has been explored, most notably in ocular (corneal) and dermal wound settings.
However, direct human clinical evidence for TB-500 itself is very limited. A 2026 scoping review of Thymosin Beta-4 and TB-500 in tissue healing and musculoskeletal repair found that the mapped literature "remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications," and noted that direct TB-500 evidence was confined to a single included study. In other words, much of the enthusiasm around TB-500 rests on mechanistic and animal work; confirming which of those effects translate to robust human outcomes is an area of ongoing research, not settled fact. Treating preclinical findings as proven human benefits is exactly the mistake this field is prone to, and we won't make it here.
For research applications, identity and purity are what separate a usable reference compound from an unknown. The TB-500 we supply to the research community is a lyophilized powder tested to 99% purity by HPLC, with a third-party Certificate of Analysis (COA) available for each lot, strictly for in-vitro laboratory use:
New to handling lyophilized peptides? See our Research Center for storage, reconstitution and COA guidance.
TB-500 is a synthetic peptide related to the actin-binding region of Thymosin Beta-4 (TΞ²4), a naturally occurring 43-amino-acid peptide that is the major actin-sequestering molecule in mammalian cells. In research settings TB-500 is used as a laboratory reference compound to study the tissue-repair pathways associated with Thymosin Beta-4.
Thymosin Beta-4 binds and sequesters actin, which is central to cell movement. In cell and animal models the peptide has been associated with promotion of cell migration, blood-vessel formation (angiogenesis), cell survival and down-regulation of inflammatory signaling. These are mechanisms observed in the laboratory, not established human clinical outcomes.
No. TB-500 sold for laboratory research is strictly for in-vitro and analytical use. It is not a drug and is not approved for human or animal use. In July 2026 TB-500 was one of several peptides reviewed by the FDA's Pharmacy Compounding Advisory Committee for possible inclusion on the 503A bulk drug substances list, but that review is separate from approval as a marketed medicine.
Human evidence for Thymosin Beta-4 has been concentrated in areas such as corneal and dermal wound repair, while direct clinical evidence for TB-500 itself is very limited. A 2026 scoping review concluded the literature remains unevenly distributed and largely preclinical, with limited human data directly relevant to musculoskeletal applications.